Cerus (NASDAQ:CERS) Earns "Sell (E+)" Rating from Weiss Ratings

Key Points

• Cerus Corporation's stock received a "sell (E+)" rating from Weiss Ratings, indicating negative sentiment among analysts.
• The company reported a quarterly earnings miss with an earnings per share of ($0.03), falling short of the expected ($0.02), despite its revenue surpassing estimates at $60.1 million.
• Institutional investors hold 78.37% of Cerus' stock, with notable increases in stakes from firms like Acadian Asset Management and Wealth Enhancement Advisory Services.

Cerus (NASDAQ:CERS - Get Free Report)'s stock had its "sell (e+)" rating reiterated by equities research analysts at Weiss Ratings in a report released on Friday,Weiss Ratings reports.

Cerus Stock Performance

CERS traded up $0.02 during trading on Friday, reaching $1.53. 687,600 shares of the company were exchanged, compared to its average volume of 1,277,315. Cerus has a 52 week low of $1.12 and a 52 week high of $2.24. The company has a current ratio of 2.00, a quick ratio of 1.35 and a debt-to-equity ratio of 1.01. The firm has a 50 day moving average of $1.42 and a 200 day moving average of $1.37. The stock has a market cap of $293.30 million, a P/E ratio of -15.30 and a beta of 1.70.

Cerus (NASDAQ:CERS - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by ($0.01). The business had revenue of $60.10 million for the quarter, compared to analyst estimates of $51.80 million. Cerus had a negative return on equity of 33.77% and a negative net margin of 9.81%. Cerus has set its FY 2025 guidance at EPS. On average, sell-side analysts forecast that Cerus will post -0.08 EPS for the current fiscal year.

Institutional Investors Weigh In On Cerus

Institutional investors have recently added to or reduced their stakes in the company. Acadian Asset Management LLC raised its holdings in shares of Cerus by 112.5% in the 1st quarter. Acadian Asset Management LLC now owns 1,898,621 shares of the biotechnology company's stock worth $2,637,000 after purchasing an additional 1,005,079 shares in the last quarter. Wealth Enhancement Advisory Services LLC grew its holdings in shares of Cerus by 218.5% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 50,972 shares of the biotechnology company's stock worth $71,000 after acquiring an additional 34,968 shares during the last quarter. Rhumbline Advisers lifted its holdings in shares of Cerus by 5.5% during the first quarter. Rhumbline Advisers now owns 251,907 shares of the biotechnology company's stock valued at $350,000 after purchasing an additional 13,112 shares during the last quarter. R Squared Ltd boosted its position in shares of Cerus by 106.7% in the 1st quarter. R Squared Ltd now owns 38,655 shares of the biotechnology company's stock valued at $54,000 after purchasing an additional 19,955 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its stake in Cerus by 6.5% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 1,774,137 shares of the biotechnology company's stock worth $2,466,000 after purchasing an additional 107,771 shares in the last quarter. 78.37% of the stock is currently owned by institutional investors and hedge funds.

Cerus Company Profile

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.